Evinacumab Treatment of Homozygous Familial Hypercholesterolemia Patients in a Real-World Setting: An Overview After the First Year of Therapy.

Laura Volpi, Dominik Spira, Knut Mai, Ilja Demuth, Elisabeth Steinhagen-Thiessen, Ursula Kassner, Thomas Bobbert

Abstract read

In one paragraph

Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Is FH a curable disease?Global cardiology science & practice · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Laura VolpiCharité - Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Endocrinology and Metabolism, European Reference Network on Rare Endocrine Diseases (ENDO-ERN), Berlin, Germany.

Dominik SpiraCharité - Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Endocrinology and Metabolism, European Reference Network on Rare Endocrine Diseases (ENDO-ERN), Berlin, Germany.

Knut MaiCharité - Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Endocrinology and Metabolism, European Reference Network on Rare Endocrine Diseases (ENDO-ERN), Berlin, Germany.

Ilja DemuthCharité - Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Endocrinology and Metabolism, European Reference Network on Rare Endocrine Diseases (ENDO-ERN), Berlin, Germany.

Elisabeth Steinhagen-ThiessenCharité - Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Endocrinology and Metabolism, European Reference Network on Rare Endocrine Diseases (ENDO-ERN), Berlin, Germany.

Ursula KassnerCharité - Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Endocrinology and Metabolism, European Reference Network on Rare Endocrine Diseases (ENDO-ERN), Berlin, Germany.

Thomas BobbertCharité - Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Endocrinology and Metabolism, European Reference Network on Rare Endocrine Diseases (ENDO-ERN), Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Homozygous familial hypercholesterolemia (HoFH) is a genetic disorder characterized by lifelong low-density lipoprotein cholesterol (LDL-C) elevation, which results in early onset of atherosclerotic cardiovascular disease. Recently, evinacumab, an angiopoietin-like 3 protein inhibitor, became available to treat patients affected by HoFH. We aimed to investigate safety and efficacy data in HoFH in clinical practice. Methods: Our HoFH cohort ( Results: An average decrease from baseline in LDL-C of -68.9 ± 14.0% ( Conclusion: Evinacumab on top of the best standard of care treatment is an effective treatment to further reduce LDL-C levels in HoFH patients.

Indexed as

angiopoietin-like 3 protein inhibitorsevinacumabhomozygous familial hypercholesterolemia

Identifiers

PMID42491512

DOI10.1016/j.aed.2026.03.004

PMCPMC13377962

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.